^
    3ms
    A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Nanjing Bioheng Biotech Co., Ltd.
    New P1 trial
    |
    fludarabine IV • CTD-402
    4ms
    CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (clinicaltrials.gov)
    P1, N=15, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Oct 2024 --> Jun 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date
    |
    cyclophosphamide • fludarabine IV • CTD-402
    9ms
    RD13-02: CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies (clinicaltrials.gov)
    P2, N=14, Completed, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Completed | N=22 --> 14 | Trial completion date: Sep 2025 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    12ms
    RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Wuhan Union Hospital, China
    New P1 trial
    |
    CTD-402
    1year
    RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=6, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=10 --> 6 | Trial completion date: Jun 2026 --> Aug 2024 | Trial primary completion date: Jun 2025 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    1year
    RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=4, Completed, Xiaoyu Zhu | Recruiting --> Completed | N=12 --> 4 | Trial completion date: Apr 2025 --> Aug 2024 | Trial primary completion date: Apr 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    1year
    Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) (clinicaltrials.gov)
    P1, N=8, Completed, Kai Lin Xu，MD | Recruiting --> Completed | N=18 --> 8 | Trial completion date: Mar 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    1year
    BHCT-RD13-02-02: CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL (clinicaltrials.gov)
    P1, N=20, Completed, He Huang | Recruiting --> Completed | Trial completion date: May 2025 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    1year
    CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    |
    cyclophosphamide • CTD-402
    over2years
    Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma (clinicaltrials.gov)
    P1, N=35, Not yet recruiting, Zhao Weili
    New P1 trial • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CTD-402
    over2years
    RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies (clinicaltrials.gov)
    P1, N=10, Recruiting, Henan Cancer Hospital
    New P1 trial
    |
    CD7 (CD7 Molecule)
    |
    CTD-402